Zai Lab Limited(ZLAB) Stock Research - Grey Stern Research
Loading...

Zai Lab Limited (ZLAB) Stock Analysis

$28.53 (-5.42%)

ZLAB Financial Performance


Use the table below to view Zai Lab Limited's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $29.20 -
52 Week Low $13.48 -
52 Week High $36.60 -
Market Cap $3.2 Billion 12/15
Gross Margin 64% 14/15
Profit Margin -41% 8/15
EBITDA margin -37% 6/15
Q3 - 2024 Revenue $102.3 Million 7/15
Q3 - 2024 Earnings -$41.7 Million 7/15
Q3 - 2024 Free Cash Flow -$56.7 Million 10/15
Trailing 4 Quarters Revenue $355.7 Million 8/15
Trailing 4 Quarters Earnings -$270.8 Million 9/15
Quarterly Earnings Growth 40% 5/15
Annual Earnings Growth 37% 8/15
Quarterly Revenue Growth 48% 5/15
Annual Revenue Growth 29% 8/15
Cash On Hand $616.1 Million 4/15
Short Term Debt $119.6 Million 2/15
Long Term Debt $6.1 Million 14/15

Zai Lab Limited Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Zai Lab Limited's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/15
PS 8.88 10/15
PB 4.73 10/15
PC 5.13 13/15
Liabilities to Equity 0.48 7/15
ROA -0.27 10/15
ROE -0.41 9/15
Current Ratio 3.10 7/15
Quick Ratio 1.94 7/15
Long Term Debt to Equity 0.01 12/15
Debt to Equity 0.19 7/15
Burn Rate 8.58 2/15
Cash to Cap 0.20 3/15
CCR 1.36 2/15
EV to EBITDA -70.09 8/15
EV to Revenue 7.50 11/15

Company Details

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

CEO: Dr. Ying Du

Website: https://www.zailaboratory.com

Address: 4560 Jinke Road, Bldg. 1, 4F, Pudong Shanghai, SHANGHAI

Exchange: NASDAQ Global Market

Industry: Biotechnology

Zai Lab Limited Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Zai Lab Limited. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Alnylam Pharmaceuticals, Inc. ALNY $32.5 Billion
Seagen Inc. SGEN $43.2 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Madrigal Pharmaceuticals, Inc. MDGL $7.0 Billion
PTC Therapeutics, Inc. PTCT $3.9 Billion
Blueprint Medicines Corporation BPMC $6.1 Billion
Apellis Pharmaceuticals, Inc. APLS $4.3 Billion
Krystal Biotech, Inc. KRYS $5.3 Billion
Ascendis Pharma A/S ASND $7.8 Billion
Legend Biotech Corporation LEGN $8.0 Billion
C4 Therapeutics, Inc. CCCC $286.6 Million
Prometheus Biosciences, Inc. RXDX $9.6 Billion
Erasca, Inc. ERAS $868.0 Million
Roivant Sciences Ltd. ROIV $8.8 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ZLAB Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 102.3 Million -$41.7 Million
Q2 2024 $ 100.5 Million -$80.3 Million
Q1 2024 $ 87.1 Million -$53.5 Million
Q4 2023 $ 65.8 Million -$95.4 Million
Q3 2023 $ 69.2 Million -$69.2 Million
Q2 2023 $ 68.9 Million -$120.9 Million
Q1 2023 $ 62.8 Million -$28.8 Million
Q4 2022 $ 62.6 Million -$26.2 Million

View All

ZLAB Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $616.1 Million $985.3 Million $125.7 Million $667.7 Million
Q2 2024 $730.0 Million $987.4 Million $83.7 Million $704.2 Million
Q1 2024 $650.8 Million $988.4 Million $63.3 Million $762.2 Million
Q4 2023 $790.2 Million $1.0 Billion $15.2 Million $796.1 Million
Q3 2023 $788.8 Million $1.0 Billion $16.7 Million $881.0 Million
Q2 2023 $859.2 Million $1.1 Billion $19.1 Million $932.3 Million
Q1 2023 $879.8 Million $1.2 Billion $20.3 Million $1.0 Billion
Q4 2022 $1.0 Billion $1.2 Billion $20.4 Million $1.0 Billion

View All

ZLAB Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$56.7 Million -$29.9 Million -$14.0 Million
Q2 2024 -$43.0 Million -$875,000 -$20.7 Million
Q1 2024 -$103.1 Million -$13.0 Million -$39.4 Million
Q4 2023 -$15.8 Million -$843,000 $1.3 Million
Q3 2023 -$57.0 Million -$1.8 Million -$70.3 Million
Q2 2023 -$61.1 Million -$2.3 Million -$19.9 Million
Q1 2023 -$72.8 Million -$3.5 Million -$128.4 Million
Q4 2022 -$113.7 Million -$4.4 Million -$111.0 Million

View All